DALLAS--(BUSINESS WIRE)--
Lantern Pharma Inc., is a clinical stage biotech company pioneering the
field of precision oncology driven by advanced genomics and machine
learning-based artificial intelligence (AI) techniques. Lantern today
announced that will present at the 9th Annual Biotech Showcase™ on
Wednesday, January 11, 2017 at the Hilton San Francisco Union Square.
Taking place during one of the industry’s largest annual healthcare
investor conferences, this conference attracts investors and
pharmaceutical executives from around the world focused on investment
and business, partnership development opportunities in the bio-tech
industry.
Lantern will present on Wednesday, January 11, 2017 at 2:45 p.m. PST, in
Room 1 (Ballroom Level). Arun Asaithambi, Ph.D., Chief Executive
Officer, will provide an overview of the company, including its
precision-oncology programs.
About Lantern Pharma Inc
Lantern Pharma is a clinical stage biotech company is aiming to
re-invent the cancer drug development process by tailoring promising
drug programs to the right cancer patients through biomarker discovery.
Lantern leverages advanced genomics and machine learning based
artificial intelligence (AI) techniques to both identify and
significantly reduce the cost and overall risk profile of new therapies
compared to traditional drug development. Lantern currently has three
clinical stage candidates in its pipeline. LP-300(Tavocept) is a phase 2
clinical candidate. LP-184 is being prepared for biomarker based
clinical trials. Irofulven-1 has been licensed out to a later stage
pharma company focused on continuing its development.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170108005041/en/
Lantern Pharma, Inc.
Arun Asaithambi, PhD
info@lanternpharma.com
www.lanternpharma.com
Source: Lantern Pharma Inc.
Released January 8, 2017